Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Advanced Biomed Inc. Common Stock (ADVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ADVB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.56 - 4.10 | Updated Date 06/21/2025 |
52 Weeks Range 0.56 - 4.10 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Advanced Biomed Inc. Common Stock
Company Overview
History and Background
There is no publicly traded company called Advanced Biomed Inc. Common Stock. As such, providing its history is impossible. This response will proceed under the hypothetical that it is a new company in the biomedical field.
Core Business Areas
- Pharmaceutical Development: Development of novel drugs and therapies.
- Medical Device Manufacturing: Production of medical devices for diagnostics and treatment.
- Biotechnology Research: Conducting research and development in biotechnology.
Leadership and Structure
Hypothetically led by a CEO, CFO, and a board of directors. Likely structured with research and development, manufacturing, sales, and marketing departments.
Top Products and Market Share
Key Offerings
- Novel Drug X: Hypothetical new drug for treating condition Y. Market share is unknown as it is a new product. Competitors include pharmaceutical giants like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK).
- Diagnostic Device Z: Hypothetical diagnostic device for early detection of disease A. Market share is unknown as it is a new product. Competitors include Roche (RHHBY) and Siemens Healthineers (SIEGY).
Market Dynamics
Industry Overview
The biomedical industry is characterized by high research and development costs, stringent regulatory requirements, and rapid technological advancements.
Positioning
As a hypothetical new company, Advanced Biomed Inc. would be trying to establish itself in the market through innovation and strategic partnerships.
Total Addressable Market (TAM)
The global biomedical market is estimated to be in the trillions of dollars. Advanced Biomed Inc.'s positioning relative to this TAM would depend on its specific products and market penetration strategies.
Upturn SWOT Analysis
Strengths
- Innovative technologies
- Strong research and development team
- Potential for high growth
- Agile and adaptable to market changes
Weaknesses
- Limited financial resources
- Lack of established market presence
- High regulatory hurdles
- Dependence on successful product development
Opportunities
- Strategic partnerships with larger companies
- Expansion into new markets
- Acquisition of smaller companies with complementary technologies
- Increased funding opportunities for biomedical research
Threats
- Competition from established players
- Changing regulatory landscape
- Patent disputes
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- JNJ
- MRK
- RHHBY
- SIEGY
Competitive Landscape
Advanced Biomed Inc. would face significant competition from established players with greater resources and market presence. Success would depend on differentiating its products and executing its strategy effectively.
Growth Trajectory and Initiatives
Historical Growth: No historical data available.
Future Projections: Future growth would depend on successful product launches and market penetration. Analyst estimates would be speculative.
Recent Initiatives: Hypothetical initiatives could include securing funding, conducting clinical trials, and forming strategic partnerships.
Summary
Advanced Biomed Inc. is a hypothetical new company facing the challenges of the competitive biomedical industry. Success hinges on its innovative products, securing funding, navigating regulatory hurdles, and effective market penetration. The company must prioritize establishing a strong market presence and forging strategic partnerships. Careful management of resources and adapting to industry changes will be crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and publicly available information about competitors.
Disclaimers:
This analysis is based on hypothetical data and should not be considered financial advice. The information provided is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Advanced Biomed Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2025-03-06 | CEO & Chairman Dr. Yi Lu Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 40 | Website https://www.advanbiomed.com |
Full time employees 40 | Website https://www.advanbiomed.com | ||
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.